TSHA Relative Valuation
TSHA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TSHA is overvalued; if below, it's undervalued.
Historical Valuation
Taysha Gene Therapies Inc (TSHA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -4.36. The fair price of Taysha Gene Therapies Inc (TSHA) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 4.92 USD , Taysha Gene Therapies Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：4.92
Fair
Undervalued
-12.16
PE
1Y
3Y
5Y
Trailing
Forward
-7.12
EV/EBITDA
Taysha Gene Therapies Inc. (TSHA) has a current EV/EBITDA of -7.12. The 5-year average EV/EBITDA is -3.18. The thresholds are as follows: Strongly Undervalued below -8.63, Undervalued between -8.63 and -5.90, Fairly Valued between -0.45 and -5.90, Overvalued between -0.45 and 2.28, and Strongly Overvalued above 2.28. The current Forward EV/EBITDA of -7.12 falls within the Undervalued range.
-6.97
EV/EBIT
Taysha Gene Therapies Inc. (TSHA) has a current EV/EBIT of -6.97. The 5-year average EV/EBIT is -3.24. The thresholds are as follows: Strongly Undervalued below -8.26, Undervalued between -8.26 and -5.75, Fairly Valued between -0.73 and -5.75, Overvalued between -0.73 and 1.78, and Strongly Overvalued above 1.78. The current Forward EV/EBIT of -6.97 falls within the Undervalued range.
229.29
PS
Taysha Gene Therapies Inc. (TSHA) has a current PS of 229.29. The 5-year average PS is 40.20. The thresholds are as follows: Strongly Undervalued below -63.54, Undervalued between -63.54 and -11.67, Fairly Valued between 92.08 and -11.67, Overvalued between 92.08 and 143.95, and Strongly Overvalued above 143.95. The current Forward PS of 229.29 falls within the Strongly Overvalued range.
-11.24
P/OCF
Taysha Gene Therapies Inc. (TSHA) has a current P/OCF of -11.24. The 5-year average P/OCF is -5.33. The thresholds are as follows: Strongly Undervalued below -17.06, Undervalued between -17.06 and -11.20, Fairly Valued between 0.53 and -11.20, Overvalued between 0.53 and 6.40, and Strongly Overvalued above 6.40. The current Forward P/OCF of -11.24 falls within the Undervalued range.
-10.64
P/FCF
Taysha Gene Therapies Inc. (TSHA) has a current P/FCF of -10.64. The 5-year average P/FCF is -4.91. The thresholds are as follows: Strongly Undervalued below -12.20, Undervalued between -12.20 and -8.56, Fairly Valued between -1.27 and -8.56, Overvalued between -1.27 and 2.37, and Strongly Overvalued above 2.37. The current Forward P/FCF of -10.64 falls within the Undervalued range.
Taysha Gene Therapies Inc (TSHA) has a current Price-to-Book (P/B) ratio of 5.62. Compared to its 3-year average P/B ratio of 9.70 , the current P/B ratio is approximately -42.10% higher. Relative to its 5-year average P/B ratio of -18.11, the current P/B ratio is about -131.01% higher. Taysha Gene Therapies Inc (TSHA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -49.39%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -51.87% , the current FCF yield is about -100.00% lower.
6.33
P/B
Median3y
9.70
Median5y
-18.11
-6.92
FCF Yield
Median3y
-49.39
Median5y
-51.87
Competitors Valuation Multiple
The average P/S ratio for TSHA's competitors is 2.12, providing a benchmark for relative valuation. Taysha Gene Therapies Inc Corp (TSHA) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of TSHA increased by 192.49% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -4.18 to -15.06.
The secondary factor is the Margin Expansion, contributed 32.56%to the performance.
Overall, the performance of TSHA in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Taysha Gene Therapies Inc (TSHA) currently overvalued or undervalued?
What is Taysha Gene Therapies Inc (TSHA) fair value?
How does TSHA's valuation metrics compare to the industry average?
What is the current P/B ratio for Taysha Gene Therapies Inc (TSHA) as of Dec 05 2025?
What is the current FCF Yield for Taysha Gene Therapies Inc (TSHA) as of Dec 05 2025?
What is the current Forward P/E ratio for Taysha Gene Therapies Inc (TSHA) as of Dec 05 2025?